Skip to main content
. 2024 Sep 2;13(10):1771–1783. doi: 10.1002/psp4.13221

FIGURE 1.

FIGURE 1

Modeling strategy for omaveloxolone PBBM. DS, drug substance; IV, intravenous; K p, permeability constant; PBBM, physiologically based biopharmaceutics modeling; PBPK, physiologically based pharmacokinetic; P eff, effective permeability; PSD, particle size distribution.